Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026

Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026
Published
Number of pages
510

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
2400
22000
CD-ROM Mail Delivery
3300
Hard Copy Mail Delivery
4200
Electronic Access - Multi-User License
4800
soft & hard
8000

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

 

  • Global Bispecific Antibody Market Opportunity:  > US$ 10 Billion
  • Global Bispecific Antibody Market Growth:  118% CAGR (2015 -2019)
  • Global Bispecific Antibody Market Growth In 2019:  280% (> US$ 1.5 Billion)
  • Global Bispecific Antibody Pipeline:  333 Drug
  • Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
  • Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

 

“Global Bispecific Antibody Market Opportunity, Drug Sales  & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto & Hemlibra) commercially available  bispecific antibodies with their regional level revenue, market share and the clinical profile.

 

"Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019"

 

The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.

 

Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.

 

“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.” 

 

Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be  achieved in next five year timeframe.

1. Introduction to Bispecific Monoclonal Antibody

 

  1.1 Overview of Monoclonal Antibody

  1.2 Overview of Bispecific Monoclonal Antibody

  1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

 

2. The Engineering & Development of Bispecific Antibodies

 

  2.1 Bispecific Antibodies Similar to IgG

 

    2.1.1 Quadroma (Hybrid Hydromas) Approach

    2.1.2 “Knobs Into Holes” Approach

    2.1.3 CrossMab Approach

    2.1.4 Dual-Variable-Domain Immunoglobulin Approach

 

  2.2 Small Bispecific Antibodies

 

    2.2.1 Bispecific Diabodies

    2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

 

3. Mechanism Of Action Of Bispecific Antibody

 

  3.1 Trifunctional Antibody: Catumaxomab (Removab®)

  3.2 Blinatumomab

 

4. Applications of Bispecific Antibodies in Diagnostic & Treatment

 

  4.1 BsMAb for Diagnosis of Bacterial  & Viral Infectious Diseases

  4.2 BsMAb for Cancer Diagnostic

  4.3 BsAbs Blocking Signaling Pathways

  4.4 BsAbs Targeting Tumor Angiogenesis

  4.5 Specific Delivery of Effector Compounds to Targets

  4.6 Bispecific Antibodies & Gene Therapy

 

5. Global Bispecific Antibody Market Outlook

 

  5.1 Current Market Scenario

 

  5.2 Availability of Bispecific Antibodies

    5.2.1 Catumaxomab (Removab)

    5.2.2 Blinatumomab

    5.2.3 Emicizumab

    5.2.4 Duligotumab

    5.2.5 SAR 156597

 

6. Approved Bispecific Antibody Dosage & Price Analysis

 

  6.1 Blincyto

  6.2 Hemlibra

 

7. Approved Bispecific Antibody Sales Analysis

 

  7.1 Blincyto

  7.2 Hemlibra

 

8. Global Bispecific Antibodies Clinical Pipeline Overview

 

  8.1     By Phase

  8.2     By  Country/Region

  8.3     By  Company

  8.4     By Indication

  8.5     Orphan Designated Bispecific Antibodies

 

 

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase

 

  9.1 Research

  9.2 Preclinical

  9.3 Phase-I

  9.4 Phase-I/II

  9.5 Phase-II

  9.6 Phase-II/III

  9.7 Phase-III

 

10. Marketed Bispecific Antibodies Clinical Insight

 

  10.1 Blinatumomab - Amgen

  10.2 Emicizumab - Chugai Pharmaceutical

 

11. Global Bispecific Antibody Market Dynamics

 

  11.1 Favorable Market Parameters

  11.2 Commercialization Challenges

 

12. Global Bispecific Antibody Market Future Prospects

 

13. Competitive Landscape

 

  13.1 Ablynx

  13.2 Adimab

  13.3 Affimed Therapeutics

  13.4 Amgen

  13.5 AstraZeneca (MedImmune)

  13.6 Chugai Pharmaceutical

  13.7 Eli Lilly

  13.8 EMD Serono

  13.9 Emergent BioSolutions

  13.10 Genentech

  13.11 Genmab

  13.12 Immunomedics

  13.13 Jounce Therapeutics

  13.14 MacroGenics

  13.15 Merus

  13.16 Neovii Biotech

  13.17 NovImmune SA

  13.18 OncoMed Pharmaceuticals

  13.19 Pieris

  13.20 Regeneron Pharmaceuticals

  13.21 Roche

  13.22 Sanofi

Figure 1-1: Advantages of Bispecific Antibodies

 

Figure 2-1: Types of Approaches to Form IgG like Bispecific Antibodies

Figure 2-2: Method of Formation of Hybrid Hybridoma

Figure 2-3: Limitations of Hybrid Hybridoma

Figure 2-4: Steps involved in “Knobs into Holes” Approach

Figure 2-5: Three different CrossMabs are Obtained by Three Different Modifications

Figure 2-6: Method for formation of Dual-Variable-Domain Immunoglobulin

Figure 2-7: Advantages of Dual Variable Domain Immunoglobulin approach

Figure 2-8: Types of Bispecific Antibodies

 

Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody

Figure 3-2: Mechanism of Action of Catumaxomab

Figure 3-3: Mechanism of Action of Blinatumomab

 

Figure 4-1: Applications of Bispecific Antibodies

 

Figure 5-1: Global - Bispecific Antibody Market Size (US$ Million), 2015 - 2019

Figure 5-2: US v/s ROW - Bispecific Antibody Market Share (%)  , 2018

Figure 5-3: US v/s ROW - Bispecific Antibody Market Share (%)  , 2019

Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra)  , 2018 & 2019

Figure 5-5: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra)  , 2018

Figure 5-6: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra)  , 2019

Figure 5-7: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra),  2019

 

 

Figure 6-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December’2019

Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , December’2019

Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December’2019

Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December’2019

Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December’2019

Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December’2019

Figure 6-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December’2019

Figure 6-8: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December’2019

Figure 6-9: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December’2019

Figure 6-10: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December’2019

 

Figure 7-1: Blincyto - Sales Value (US$ Million), 2015 - 2019

Figure 7-2: US - Blincyto Sales Value (US$ Million), 2016 - 2019

Figure 7-3: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2019

Figure 7-4: Blincyto - Quarterly Sales Value (US$ Million), 2018

Figure 7-5: Blincyto - Quarterly Sales Value (US$ Million), 2019

Figure 7-6: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018

Figure 7-7: Blincyto - US v/s Rest of World Share in Sales Value (%),  2019

Figure 7-8: Hemlibra - Sales Value by Countries (US$ Million), 2019

Figure 7-9: Hemlibra - Sales Value by Countries (US$ Million), 2018

Figure 7-10: Hemlibra - Sales Value Share by Countries (%), 2018

Figure 7-11: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018

Figure 7-12: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019

Figure 7-13: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019

Figure 7-14: Hemlibra - Quarterly Sales Value (US$ Million), 2019

Figure 7-15: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019

Figure 7-16: Hemlibra - 9 Month Sales Value Share by countries (%), 2019

 

Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2020 till 2026

Figure 8-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2020 till 2026

Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2020 till 2026

Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2020 till 2026

Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2020 till 2026

Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2020 till 2026

 

Figure 11-1:  Favorable Market Parameters Global Bispecific Antibody Market

Figure 11-2: Commercialization Challenges for Bispecific Antibody

 

Figure 12-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2020 – 2026

 

Figure 13-1: Ablynx - Clinical Pipeline

Figure 13-2: Affimed Therapeutics - Clinical Pipeline

Figure 13-3: Amgen - Clinical Pipeline

Figure 13-4: EMD Serono - Clinical Pipeline

Figure 13-5: Emergent Bioscience - Clinical Pipeline

Figure 13-6: Genmab - Clinical Pipeline

Figure 13-7: Jounce Therapeutics - Clinical Pipeline

Figure 13-8: MacroGenics - Clinical Pipeline

Figure 13-9: Merus - Clinical Pipeline

Figure 13-10: Novimmune - Clinical Pipeline

Figure 13-11: OncoMed - Clinical Pipeline

Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline

Figure 13-13: Roche - Clinical Pipeline

 

 

List of Tables

 

Table 2-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method

Table 2-2: List of Bispecific Antibodies Formed by DART

Table 2-3: List of Bispecific Antibodies Formed by BiTE Method

Table 2-4: List of Other BiTEs

Table 4-1: Bispecific Antibodies Targeting Cancer